FDA Accepts BLA for Imsidolimab in Generalized Pustular Psoriasis
FDA accepts for review a BLA for imsidolimab, an IL-36–targeting monoclonal antibody, as a treatment for generalized pustular psoriasis, a rare and potentially fatal neutrophilic disease.